Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1995-06-05
1997-12-16
Knode, Marian C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
4242241, 4242331, 4352351, 4353201, 935 32, 935 34, 935 57, 935 65, A61K 3912, A61K 39205, C12N 1500, C12N 700
Patent
active
056982020
ABSTRACT:
A method of vaccinating a human or animal against rabies is provided by administering a replication defective recombinant adenovirus containing a complete deletion of its E1 gene and at least a partial deletion of its E3 gene, said virus containing in the site of the E1 deletion a sequence comprising a non-adenovirus promoter directing the replication and expression of DNA encoding a rabies virus G protein, which, when administered to the animal or human in said recombinant virus, elicits a substantially complete protective immune response against rabies virus.
REFERENCES:
patent: 4393201 (1983-07-01), Curtis et al.
Levrevo, M. et al, 1990, Gene, pp. 195-202.
K. Charlton et al, "Oral Rabies Vaccination of Skunks and Foxes with a Recombinant Human Adenovirus Vaccine", Arch. Virol., 123:169-179 (1992).
D. Johnson et al, "Abundant Expression of Herpes Simplex Virus Glycoprotein gb Using an Adenovirus Vector", Virology, 164:1-14 (1988).
R. Dewar et al, "Synthesis and Processing of Human Immunodeficiency Virus type 1 Envelope Proteins Encoded by a Recombinant Human Adenovirus", J. Virol., 63(1):129-136 (Jan., 1989).
B. Brochier et al, "Towards Rabies Elimination in Belgium by Fox Vaccination Using a Vaccinia-Rabies Glycoprotein Recombinant Virus", Vaccine, 12(15):1368-1371 (Nov., 1994).
L. Prevec et al, "A Recombinant Human Adenovirus Vaccine Against Rabies", J. Infect. Dis., 161:27-30 (Jan., 1990).
K. Kozarsky et al, "In Vivo Correction of Low Density Lipoprotein Receptor Deficiency in the Watanabe Heritable Hyperlipidemic Rabbit with Recombinant Adenoviruses", J. Biol. Chem., 269(18):13695-13702 (May 6,
K. Kozarsky et al, "Adenovirus-Mediated Correction of the Genetic Defect in Hepatocytes from Patients with Familial Hypercholesterolemia", Somatic
K. Kozarsky et al, "Gene Therapy: Adenovirus Vectors", Curr. Opin. Genet.
Y. Yang et al, "MHC Class I-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant
Y. Yang et al, "Cellular Immunity to Viral Antigens Limits E1-Deleted Adenoviruses for Gene Therapy", Proc. Natl. Acad. Sci. USA, 91:4407-4411
Y. Yang et al, "Inactivation of E2a in Recombinant Adenoviruses Improves the Prospect for Gene Therapy in Cystic Fibrosis", Nature Genetics,
S. Ishibashi et al, "Hypercholesterolemia in Low Density Lipoprotein Receptor Knockout Mice and its Reversal by Adenovirus-Mediated Gene Delivery", J. Clin. Invest., 92:883-893 (Aug., 1993).
J. Engelhardt et al, "Ablation of E2A in Recombinant Adenoviruses Improves Transgene Persistence and Decreases Inflammatory Response in Mouse Liver",
J. Engelhardt et al, "Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Biological Efficacy Study", Human Genet. Ther.,
J. Engelhardt et al, "Prolonged Transgene Expression in Cotton Rat Lung with Recombinant Adenoviruses Defective in E2a", Human Gene Ther.,
M Horwitz, "Adenoviridae and Their Replication", Virology, 2d edition, ed. B. N. Fields, Raven Press, Ltd., New York, Chapter 60, pp. 1679-1721 (1990).
M. Boshart et al, "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus", Cell, 41:521-530 (Jun., 1985).
K. Fisher et al, "Biochemical and Functional Analysis of an Adenovirus-Based Ligand Complex for Gene Transfer", Biochem. J., 299:49-58 (Apr. 1, 1994).
T. Shenk et al, "Genetic Analysis of Adenoviruses", Current Topics in Microbiol. and Immunol., 111:1-39 (1984).
M. Rosenfeld et al, "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 68:143-155 (Jan. 10, 1992).
J. Logan et al, "Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection", Proc. Natl. Acad. Sci. USA, 81:3655-3659 (Jun., 1984).
P. Van Der Vliet et al, "Thermolabile DNA Binding Proteins from Cells Infected with a Temperature-Sensitive Mutant of Adenovirus Defective in Viral DNA Synthesis", J. Virol., 15(2):348-354 (Feb., 1975).
M. Eloit et al, "Construction of a Defective Adenovirus Vector Expressing the Pseudorabies Virus Glycoprotein gp50 and its Use as a Live Vaccine", J. Gen. Virol., 71(10):2425-2431 (Oct., 1990).
S. Jacobs et al, "High-Level Expression of the Tick-Borne Encephalitis Virus NS1 Protein by Using an Adenovirus-based Vector: Protection Elicited in a Murine Model", J. Virol., 66:2086-2095 (Apr., 1992).
T. Ragot et al, "Replication-Defective Recombinant Adenovirus Expressing the Epstein-Barr Virus (EBV) Envelope Glycoprotein gp340/220 Induces Protective Immunity Against EBV-induced Lymphomas in the Cottontop Tamarin", J. Gen. Virol., 74(3):501-507 (Mar., 1993).
Ertl Hildegund C. J.
Wilson James M.
Knode Marian C.
Salimi Ali R.
The Trustees of the University of Pennsylvania
The Wistar Institute of Anatomy & Biology
LandOfFree
Replication-defective adenovirus human type 5 recombinant as a r does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Replication-defective adenovirus human type 5 recombinant as a r, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Replication-defective adenovirus human type 5 recombinant as a r will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-203019